280582-13-0

Usage

Derivative of pyrimidine

Pyrimidine is a heterocyclic aromatic organic compound, and 2,5-dichloro-N-(4-fluorophenyl)pyrimidin-4-amine is a modified version of it, which means its structure is based on the pyrimidine ring.

Two chlorine atoms

The compound contains two chlorine atoms, which are covalently bonded to the pyrimidine ring and contribute to its chemical reactivity and properties.

One fluorine atom

The presence of a single fluorine atom in the compound affects its electronic properties and reactivity, as fluorine is highly electronegative.

Phenyl group

A phenyl group (a ring structure with six carbon atoms and alternating single and double bonds) is attached to the pyrimidine ring, which influences the compound's chemical behavior and properties.

Amine group

The presence of an amine group (a nitrogen atom bonded to two alkyl or aryl groups) in the compound provides a basic character and allows for the formation of various chemical bonds with other molecules.

Potential applications in the pharmaceutical industry

Due to its biological activity, 2,5-dichloro-N-(4-fluorophenyl)pyrimidin-4-amine may be used in the development of drugs or other therapeutic agents.

Used in the synthesis of various organic compounds

The compound can be used as a building block or reactant in the creation of other organic molecules, which may have various applications in different fields.

Varies in specific uses and properties

The exact properties and applications of 2,5-dichloro-N-(4-fluorophenyl)pyrimidin-4-amine can differ depending on the specific research or chemical process it is involved in, making it a versatile compound in the field of chemistry.

Upstream product

• 5750-76-5 2,4,5-trichloropyrimidine 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1341200-77-8 2-((2,5-dichloropyrimidin-4-yl)amino)-5-fluorobenzene-1-sulfonyl chloride 
• 1341200-78-9 2,5-dichloro-N-(4-fluoro-2-(morpholinosulfonyl)phenyl)pyrimidin-4-amine 
• 1341200-53-0 5-chloro-N₄-(4-fluoro-2-(morpholinosulfonyl)phenyl)-N₂-(4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrimidine-2,4-diamine 
• 1341200-79-0 2,5-dichloro-N-(4-fluoro-2-(pyrrolidin-1-ylsulfonyl)phenyl)pyrimidin-4-amine 
• 1341200-54-1 5-chloro-N₄-(4-fluoro-2-(pyrrolidin-1-ylsulfonyl)phenyl)-N₂-(4-((4-methylpiperazin-1-yl)methyl)phenyl)pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

Discovery and in Vivo Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor

Cathepsin C (Cat C) participates in inflammation and immune regulation by affecting the activation of neutrophil serine proteases (NSPs). Therefore, cathepsin C is an attractive target for treatment of NSP-related inflammatory diseases. Here, the complete discovery process of the first potent "non-peptidyl non-covalent cathepsin C inhibitor"was described with hit finding, structure optimization, and lead discovery. Starting with hit 14, structure-based optimization and structure-activity relationship study were comprehensively carried out, and lead compound 54 was discovered as a potent drug-like cathepsin C inhibitor both in vivo and in vitro. Also, compound 54 (with cathepsin C Enz IC50 = 57.4 nM) exhibited effective anti-inflammatory activity in an animal model of chronic obstructive pulmonary disease. These results confirmed that the non-peptidyl and non-covalent derivative could be used as an effective cathepsin C inhibitor and encouraged us to continue further drug discovery on the basis of this finding.

Discovery and SARs of 5-Chloro- N4-phenyl- N2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives as Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Cyclin-dependent kinases (CDKs) are promising therapeutic targets for cancer therapy. Herein, we describe our efforts toward the discovery of a series of 5-chloro-N4-phenyl-N2-(pyridin-2-yl)pyrimidine-2,4-diamine derivatives as dual CDK6 and 9 inhibitors. Intensive structural modifications lead to the identification of compound 66 as the most active dual CDK6/9 inhibitor with balancing potency against these two targets and good selectivity over CDK2. Further biological studies revealed that compound 66 was directly bound to CDK6/9, resulting in suppression of their downstream signaling pathway and inhibition of cell proliferation by blocking cell cycle progression and inducing cellular apoptosis. More importantly, compound 66 significantly inhibited tumor growth in a xenograft mouse model with no obvious toxicity, indicating the promising therapeutic potential of CDK6/9 dual inhibitors for cancer treatment. Therefore, the above results are of great importance in the development of dual CDK6/9 inhibitors for cancer therapy.

Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies

Concurrent inhibition of Janus kinase (JAK) and histone deacetylase (HDAC) could potentially improve the efficacy of the HDAC inhibitors in the treatment of cancers and resolve the problem of HDAC inhibitor resistance in some tumors. Here, a novel series

JAK (Janus kinase) and HDAC (histone deacetylase) double-target-spot inhibitor with 4-aminopyrazole structure, and preparation method and application thereof

The invention relates to a JAK (Janus kinase) and HDAC (histone deacetylase) double-target-spot inhibitor with a 4-aminopyrazole structure, a preparation method thereof and application of the compoundto preparation of drugs for preventing or treating bloo

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors

Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer. Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivatives as potent JAKs inhibitors for cancer treatment. Res

Design, synthesis, and biological evaluation of a series of novel AXL kinase inhibitors

The receptor tyrosine kinase AXL has emerged in recent years as an potential oncology target due to its overexpression in several types of cancers coupled with its ability to promote tumor growth and metastasis. To identify small molecule inhibitors of AXL, we built a homology model of its catalytic domain to virtually screen and identify scaffolds displaying an affinity for AXL. Further computational and structure-based design resulted in the synthesis of a series of 2,4,5-trisubstitued pyrimidines, which demonstrated potent inhibition of AXL in vitro (IC50 = 19 nM) and strongly inhibited the growth of several pancreatic cell lines.